NK Cell Therapy Recurrent/Refractory Elderly AML | NCT04599452

NCT04599452

Protocol Section

Identification Module

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Status Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
10 patients with recurrent refractory elderly AML were treated	Experimental	The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.	Biological: Allogeneic NK cell regimen group

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Allogeneic NK cell regimen group	Biological	10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen. Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10^6/kg d13，d15.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Objective Response Rate (ORR) (PR+CR)	The proportion of patients with complete response(CR) or partial response(PR) as measured by response criteria definitions for acute myeloid leukemia	3 months

Measure	Description	Time Frame
Overall survival(OS)	The proportion of patients with overall survival(OS).	1 year

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

The 2 or more than 2-cycles of standard regimen was used to treat elderly AML patients who did not achieve complete remission or relapse.
Patients with age 60 years to 70 years.
KPS greater than or equal to 60.
ALT and AST are less than 3 times normal.
Total bilirubin less than 1.5mg/dl(25.65umol/L).
Serum creatinine less than 2.5mg/dl(221umol/L), or creatinine scavenging ability greater than or equal to 60 mL/min/1.73 m2.
Left ventricular ejection fraction cardiac greater than or equal to 45%, Echocardiography (ECHO) showed no pericardial effusion, Electrocardiogram (ECG) is normal.
No pleural effusion in lungs
Oxyhemoglobin saturation greater than or equal to 92% in normal environment.
KIR mismatch between patient and umbilical cord blood.
Volunteer to participate in the trial and sign the informed consent form.

Exclusion Criteria:

Malignant tumor patient.
Patients who are accompanied by fungal, bacterial, viral, or other uncontrolled infections or require level 4 isolation( HBV-DNA quantification and normal liver function in patients with hepatitis b infection are excluded).
Patients with HIV, HCV positive.
Patients with central nervous system diseases, including stroke, epilepsy, dementia, or autoimmune central nervous system disorders.
During the first 12 months of enrollment, patients with cardioangiography or stents, active angina pectoris or other clinically significant symptoms, or with cardiogenic asthma.
Patients receiving anticoagulant therapy or with severe coagulation disorders.
According to the researcher's judgment, the drug treatment the patient is receiving will affect the safety and effectiveness of the study.
Patients with allergies or history of allergies to biological agents used in this program.
Systemic steroid used within 2 weeks before treatment (except for recent or present use of inhaled corticosteroids).
Patients with other uncontrolled diseases, Investigators think it is not suitable for the participants.
Any circumstance that the investigator considers may increase the risk to the subject or interfere with the results of the study.
Patients participate in other clinical studies.

ID	Term
D020969	Disease Attributes
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms